Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms
Status:
Terminated
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
P276-00 is a molecule derived from Rohitukine, which through pre clinical assays was
identified as a selective Cdk4-D1 and Cdk1-B inhibitor.The inhibition of these Cdks causes
cell cycle arrest between the G1-S transition thus blocking the cell cycle events at an early
stage of development. It therefore has the potential for being efficacious with lesser side
effects.